PROGRAMAÇÃO 16 29/08/ :30 Welcome and Introduction. 8:45 Carlos H. Barrios, Md and John Marshall, MD

Transcription

1 16 29/08/2014 PROGRAMAÇÃO Challenging Cases in Oncology 8:30 Welcome and Introduction 8:45 Carlos H. Barrios, Md and John Marshall, MD Case 1: Metastatic Breast 8:45 Presentation of Case and Participant Voting 9:00 John Marshall, MD 9:00 Metastatic Breast Discussion 9:25 Sérgio Simon, MD 9:25 9:30 9:30 Demographic Questions 9:50 Case 2: Advanced Pancreas 9:55 Presentation of Case and Participant Voting 10:15 John Marshall, MD 10:15 Advanced Pancreas Discussion 10:35 Anelisa Coutinho, MD 10:35 10:40 10:45 COFFEE BREAK 11:00 Case 3: Metastatic Colorectal 11:05 Presentation of Case and Participant Voting 11:25 John Marshall, MD 11:25 Metastatic Colorectal Discussion 11:45 Gabriel Prolla, MD 11:45 11:50 Case 4: Advanced Prostate 11:50 Presentation of Case and Participant Voting 12:10 John Marshall, MD 12:10 Advanced Prostate Discussion 12:25 Ana Coradazzi, MD, PhD 12:25 12:30 12:30 Summary Comments and Adjourn 12:30 Almoço (Salão Fernando Pessoa Hotel Pestana) 14:00 Tópicos Controversos em Oncologia 14:00 15:00 15:00 15:30 15:30 15:45 15:45 16:00 16:00 17:00 17:00 18:00 Tratamento hormonal do câncer de mama metastático: novas estratégias e perspectivas futuras Presidente: Dra. Vanessa Dybal Bertoni (BA) Convidado: Dr. Antônio C. Buzaid (SP) Revisão do tratamento do câncer de próstata resistente a castração após falha de terapia de privação androgênica Presidente: Dr. Vinícius Carrera (BA) Convidado: Dr. Volney Lima (MG) Coffee Break Câncer de ovário avançado Update do tratamento em 1ª linha Presidente: Dra. Aknar Freire de Carvalho Calabrich (BA) Convidada: Dra. Angélica Nogueira (MG) Câncer de mama metastático Her 2 positivo Presidente: Carlos H. Barrios (RS) Convidado: Dr. Paul Goss (EUA) e caso clínico 18:30 Coquetel de abertura

2 30/08/ Coordenador: Vinícius Carrera (BA) 08:00-08:10 Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormonesensitive newly metastatic prostate cancer (mprca): An ECOG-led phase III randomized trial. Dr. Evanius Garcia Wierman (PR) 08:10-08:20 08:20-08:30 Genitourinary Nivolumab for metastatic renal cell carcinoma (mrcc): Results of a randomized, dose-ranging phase II trial. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Dr. Igor Morbeck (DF) Dr. Fernando Sabino Marques Monteiro (DF) 08:30-08:40 Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mrcc): Biomarker-based results from a randomized clinical trial. Dr. Fabio Schutz (SP) 08:40-08:55 DISCUSSÃO DO MÓDULO - Genitourinary Coordenador: Dr. Arthur Katz (SP) 08:55 09:05 First-line crizotinib versus pemetrexed cisplatin or pemetrexed carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) Dr. Mauro Zukin (RJ) 09:05-09:15 Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant non-small cell lung cancer (NSCLC). Dra. Aknar Freire de Carvalho Calabrich (BA) 09:15-09:25 Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. Dr. Vladimir Cláudio Cordeiro de Lima (SP) 09:25-09:35 Lung A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC- 1121B) versus DOC and placebo (PL) in the secondline treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy Dr. Marcelo Cruz (SP) 09:35-09:45 A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. Dra. Clarissa Baldoto (RJ) Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. 09:45-09:55 Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. Dra. Elisangela Carvalho (BA) 09:55-10:15 DISCUSSÃO DO MÓDULO: Lung 10:15-10:30 COFFEE BREAK

3 20 30/08/2014 HORÁRIO MÓDULO AULA AULA Coordenador: Dr. Paul Goss (EUA) 10:30-10:40 Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptorpositive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. Dr. Max Mano (SP) 10:40-10:50 First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti- HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) Dr. Carlos Barrios (RS) 10:50-11:00 Bevacizumab (Bv) in the adjuvant treatment of HER2- negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. Dra. Debora Gagliato (SP) 11:00-11:10 Breast Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors 2cm: A meta-analysis of the randomized trastuzumab trials. Dr. Ricardo Marques (SP) 11:10-11:20 Phase III trial ( Prevention of Early Menopause Study [POEMS] - SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian faillure in earlystage, hormone receptor-negative breast cancer: An international intergroup trial of SWOG, IBCSG, ECOG,and CALGB (Alliance). Dra. Candice Amorim de Araújo Lima Santos (PE) 11:20-11:30 Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000patients in 70 trials. Dr. Sergio Simon (SP) 11:30-11:40 Association of genomic analysis of imune function genes and clinical outcome in the NTCTG ( Alliance) N9831 adjuvant trastuzumab trial. Dra. Vanessa Dybal (BA) 11:40 11:50 Pathological complete response (pcr) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gbrca) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. Dr. Anderson Arantes Silvestrini (RJ) 11:50-12:10 DISCUSSÃO DO MÓDULO: Breast Coordenadora: Dra. Maria da Glória Bonfim Arruda (BA) 12:10-12:20 Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. Dr. Vitor Hugo Souza (BA) 12:20-12:30 Leukemia / Lymphoma A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report. Dra. Marianna Lima (BA) 12:30-12:40 Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-gcb) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study. Dr. Marco Salvino (BA) 12:40-12:50 DISCUSSÃO DO MÓDULO: Leukemia / Lymphoma 12:50-14:00 ALMOÇO (Salão Fernando Pessoa Hotel Pestana)

4 30/08/ Coordenadora: Dra. Maria Del Pilar Estevez Diz (SP) 14:00-14:10 A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Dra. Daniele Assad (DF) 14:10-14:20 Gynecologic Ovarian Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Dra. Angelica Nogueira (MG) 14:20-14:30 Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. Dra. Daniela de Freitas (SP) 14:30-14:40 DISCUSSÃO DO MÓDULO: Gynecologic Ovarian Coordenador: Dr. Antonio C. Buzaid (SP) 14:40-14:50 Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-pd-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). Dr. Rodrigo Guedes (BA) 14:50-15:00 Melanoma Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC phase III trial. Dr. Rafael Schemerling (SP) 15:00-15:10 COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma Dr. Markus Andret Gifoni Cavalcante (CE) 15:10-15:25 DISCUSSÃO DO MÓDULO: Melanoma Coordenador: Dr. Olavo Feher (SP) 15:25-15:35 Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). Dra. Ana Coradazzi (SP) 15:35-15:45 15:45-15:55 Head and Neck Concomitant chemoradiation (CRT) or cetuximab/ RT (CET/RT) versus induction Docetaxel/ Cisplatin/5- Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT ). E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (ccr) to induction chemotherapy (IC). Dr. Olavo Feher (SP) Dr. Gilberto Castro Junior (SP) 15:55-16:05 A phase 3, multicenter, double-blind, placebocontrolled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). Dr. Denyei Nakazato (SP) 16:05-16:20 DISCUSSÃO DO MÓDULO: Head and Neck 16:20-16:40 COFFEE BREAK

5 22 30/08/2014 Coordenador: Dr. Paulo Hoff (SP) 16:40-16:50 Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/ leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). Prognostic impact of deficient mismatch repair (dmmr) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mcrc). CALGB/SWOG 80405: Phase III trial of irinotecan/5- FU/leucovorin (FOLFIRI) or oxaliplatin/5-fu/ leucovorin (mfolfox6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wildtype (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Dr. Frederico Costa (SP) 16:50-17:00 Dr. Rui Weschenfelder (RJ) 17:00-17:10 Gastrointestinal Colorectal Dr. Gabriel Prolla (RJ) 17:10-17:20 Dr. Fernando Meton (RJ) 17:20-17:30 Dra. Anelisa Coutinho (BA) 17:30-17:50 DISCUSSÃO DO MÓDULO: Gastrointestinal- Colorectal Coordenador: Dr. Caio Rocha Lima (EUA) 17:50-18:00 A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mpc). RAINBOW: A global, phase III, randomized, doubleblind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mgc) following disease progression on first-line platinum- and fluoropyrimidinecontaining combination therapy Efficacy analysis in Japanese and Western patients. Dr. Jorge Sabbaga (SP) 18:00-18:10 Gastrointestinal (Noncolorectal) Dra. Maria de Lourdes Oliveira (RJ) 18:10-18:20 Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. Dra. Rachel Riechelmann (SP) 18:20-18:40 DISCUSSÃO DO MÓDULO: Gastrointestinal (Noncolorectal) 18:40 ENCERRAMENTO